Alzheimer's Disease Antibody Kit

Alzheimer's Disease Antibody Sampler Kit

Cat. Num. AAA2549988

• Applications: Western Blot
• Synonyms: Alzheimer's Disease; Alzheimer's Disease Antibody Sampler Kit; Alzheimer's Disease antibody kit

• Applicable Applications for Alzheimer's Disease antibody kit: Western Blot (WB)

Western Blot (WB)

(Western Blot analysis of various cells using Amyloid-beta Polyclonal Antibody at dilution of 1:2000.)

Western Blot (WB)

(Western Blot analysis of Jurkat cells with NF-L Polyclonal Antibody.)

Western Blot (WB)

(Western Blot analysis of 293T-UV cells using Tau Polyclonal Antibody at dilution of 1:1000.)

Western Blot (WB)

(Western Blot analysis of Human fetal brain tissue using BACE1 Polyclonal Antibody at dilution of 1:500)

Western Blot (WB)

(Western Blot analysis of 293T cells using Synuclein-alpha Polyclonal Antibody at dilution of 1:500.)

Western Blot (WB)

(Western Blot analysis of Jurkat cells with GSK3alpha Polyclonal Antibody.)

Western Blot (WB)

(Western Blot analysis of Hela cells with Phospho-GSK3alpha (Ser21) Polyclonal Antibody)

Western Blot (WB)

(Western Blot analysis of Hela, Jurkat cells using GSK3alpha/beta Polyclonal Antibody at dilution of 1:1000.)

Western Blot (WB)

(Western Blot analysis of HT-29 cells using GSK3beta Polyclonal Antibody at dilution of 1:2000.)

Related Product Information for Alzheimer's Disease antibody kit

Background: Alzheimer's Disease (AD) is one of the most common neurodegenerative diseases worldwide. Clinically, it is characterized by the presence of extracellular amyloid plaques and intracellular neurofibrillary tangles, which results in neuronal dysfunction and cell death. Central to this disease is the differential processing of the integral transmembrane glycoprotein Amyloid beta (A4) precursor protein (APP) that exists as several isoforms. The amino acid sequence of APP contains the amyloid domain, which can be released by a two-step proteolytic cleavage. beta- secretase (BACE) is an aspartic acid proteinase that catalyses the initial step in APP processing by cleaving and releasing a soluble, extracellular APP-beta (sAPPbeta) ectodomain and generating a membrane-bound, carboxy- terminal fragment consisting of 99 amino acids (CTF99). Additional processing of CTF99 by gamma-secretase generates the amyloid beta-peptide (Abeta) that forms aggregates in the brains of AD patients. BACE is an attractive target for inhibitors in AD therapy since it catalyses the first and rate limiting step in amyloidogenic APP processing. Pro-BACE-1 is synthesized in the ER before it is transported to the trans-Golgi network to undergo maturation. The extracellular deposition and accumulation of the released Abeta fragments and an alpha-synuclein fragment known as the non- Abeta fragment, form the main components of amyloid plaques in AD. GSK-3alpha regulates the production of Abeta peptides. Administration of therapeutic concentrations of lithium, a GSK-3 inhibitor, attenuates Abeta production by specifically inhibiting the cleavage of APP by gamma-secretase, thereby blocking accumulation of Abeta peptides in the brains of mice that overproduce APP. AD is also characterized by the presence of neurofibrillary tangles. These tangles are the result of hyperphosphorylation and oligomerization of the microtubule associated protein Tau and lead to apoptosis of the neuron. In particular, phosphorylation of Tau Ser396 by GSK-3 or CDK5 destabilizes microtubules in AD. Additionally, neurofilaments are the major intermediate filaments found in neurons and consist of light (NFL), medium (NFM) and heavy (NFH) subunits. Accumulation of neurofilaments are found in many human neurological disorders including AD.